ArticleInternational journal of cancer2025
Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biological consistency and molecular heterogeneity in synchronous endometrial and ovarian carcinomas: a clinicopathological study within the FIGO 2023 framework.Journal of ovarian research · 2026Article
- Lynch Syndrome as a Spectrum of Four Distinct Genetic Disorders: Toward Genotype-Guided Precision Management in the NGS Era.Cancers · 2026Review
- Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lynch syndrome (LS) is a prevalent cause of hereditary gynecological cancers. DNA mismatch repair (MMR) defects are important players in LS tumorigenesis, but the developmental steps leading to malignancy are incompletely understood. We undertook a deep sequencing approach with a panel of ~1,000 cancer-associated genes to detect somatic changes in retrospective specimens from 33 LS carriers who had developed endometrial carcinoma (EC) or ovarian carcinoma (OC). Consecutive samples of atypical endometrial hyperplasia (AH) and EC or OC (64 samples plus blood) were available from a screening period of 15 years (0-15 years). Of carcinomas, all but one (41/42, 98%) were MMR-deficient by microsatellite instability or immunohistochemical analysis, and 86% (36/42) showed loss of heterozygosity or somatic variants of MMR genes as putative second hits. AH closely resembled EC and OC with respect to MMR deficiency (20/22, 91%) and the presence of second hits (16/22, 73%); moreover, the average tumor mutation burdens and top mutant genes were largely similar in hyperplasia and carcinoma. The proportion of hypermutated tumors (over 10 somatic non-synonymous mutations per megabase) was 36/42 (86%) among carcinomas and 15/22 (68%) among hyperplasia specimens (statistically non-significant difference). In individual patients, cancer-associated genes revealed varying degrees of somatic variant sharing between consecutive specimens of hyperplasia and carcinoma (10/19, 53%), and in some, such variants were detectable in histologically normal endometrium (9/19, 47%) too, one or several years before carcinoma. Our results shed light on the evolutionary trajectories of gynecological cancer development in LS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.